Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amro Forte
- Development stage
- Unknown
- Lead developer
- Taqwa Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Amro Forte** is an oral haematinic syrup marketed by Amros Pharmaceuticals and listed by Taqwa Pharmaceuticals. It is a fixed-dose combination containing ferric ammonium citrate, folic acid, pyridoxine hydrochloride, thiamine hydrochloride, and nicotinamide. The product is intended to replenish iron and vitamin cofactors involved in erythropoiesis and is used for iron-deficiency anaemia and related nutritional deficiency states.
- Brand names
- Amro ForteAmro Forte Syrup
Beyond the preview
Go deeper on Amro Forte.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amro Forte.